Monooxygenase and use in preparation of optically pure sulfoxide

US11345900B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11345900-B2
Application numberUS-201917294424-A
CountryUS
Kind codeB2
Filing dateNov 26, 2019
Priority dateNov 26, 2018
Publication dateMay 31, 2022
Grant dateMay 31, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A monooxygenase having an amino acid sequence obtained by mutation of the amino acid sequence shown in SEQ ID NO:2 is disclosed. The use of the monooxygenase of the present invention in production of chiral sulfoxide-based drugs has advantages including mild reaction conditions, environmental friendliness, high yield, high optical purity of products, less peroxide products, and the like, and therefore the monooxygenase in the present invention has a good industrial application prospect in the production of proton pump inhibitors for the treatment of gastric ulcers.

First claim

Opening claim text (preview).

What is claimed is: 1. A monooxygenase, comprising a mutant polypeptide of a parental polypeptide having the amino acid sequence shown in SEQ ID NO:2, wherein the mutant polypeptide has an oxidation activity, mutations of the mutant polypeptide comprise replacements of amino acid residues at specified positions of Xaa143, Xaa326, Xaa426, Xaa432, Xaa433, Xaa435, Xaa438, and Xaa505 and optionally at least one position selected from the group consisting of Xaa21; Xaa40; Xaa55; Xaa70; Xaa145; Xaa156; Xaa185; Xaa220; Xaa244; Xaa246; Xaa248; Xaa249; Xaa277; Xaa281; Xaa386; Xaa388; Xaa390; Xaa405; Xaa430; Xaa465; Xaa468; Xaa488; Xaa489; Xaa490; Xaa497; and Xaa501 of the amino acid sequence shown in SEQ ID NO: 2; wherein at Xaa143, L is replaced with A or P; at Xaa326, K is replaced with C or F; at Xaa426, L is replaced with F or P; at Xaa432, F is replaced with L or I; at Xaa433, T is replaced with C or A; at Xaa435, L is replaced with S; at Xaa438, S is replaced with I; and at Xaa505, F is replaced with L. 2. The monooxygenase according to claim 1 , wherein the mutations further comprise any one of the following: a) replacement of amino acid residue(s) at any 1, 2, 3, 4, or 5 positions other than the specified positions; b) deletion of amino acid residue(s) at any 1, 2, 3, 4, or 5 positions other than the specified positions; and c) insertion of amino acid residue(s) at any 1, 2, 3, 4, or 5 positions other than the specified positions. 3. The monooxygenase according to claim 1 , wherein the replacements of the amino acid residues at the specified positions further comprise any one or more of the following replacements: at the Xaa21, S is replaced with G; at the Xaa40, T is replaced with A; at the Xaa55, L is replaced with Y, W, F or N; at the Xaa70, E is replaced with G; at the Xaa145, A is replaced with S; at the Xaa156, E is replaced with G; at the Xaa185, G is replaced with A or S; at the Xaa220, M is replaced with R; at the Xaa244, L is replaced with V or I; at the Xaa246, F is replaced with Y; at the Xaa248, L is replaced with E, N, A or W; at the Xaa249, N is replaced with S; at the Xaa277, F is replaced with L, V, Y, I or D; at the Xaa281, F is replaced with V or A; at the Xaa386, N is replaced with S; at the Xaa388, I is replaced with F, C, K, G; at the Xaa390, M is replaced with S, V, I; at the Xaa405, K is replaced with M; at the Xaa430, G is replaced with T or S; at the Xaa465, K is replaced with R; at the Xaa468, V is replaced with A; at the Xaa488, E is replaced with K; at the Xaa489, S is replaced with C; at the Xaa490, W is replaced with R; at the Xaa497, P is replaced with S; and at the Xaa501, N is replaced with Y. 4. The monooxygenase according to claim 3 , wherein the replacements of the amino acid residues comprise any of the following replacements: 1) 8 replacements, wherein at the Xaa143, the L is replaced with the P; at the Xaa326, the K is replaced with the C; at the Xaa426, the L is replaced with the F; at the Xaa432, the F is replaced with the L; at the Xaa433, the T is replaced with the A; at the Xaa435, the L is replaced with the S; at the Xaa438, the S is replaced with the I; at the Xaa505, the F is replaced with the L; 2) 8 replacements, wherein at the Xaa143, the L is replaced with the A; at the Xaa326, the K is replaced with the C; at the Xaa426, the L is replaced with the F; at the Xaa432, the F is replaced with the L; at the Xaa433, the T is replaced with the A; at the Xaa435, the L is replaced with the S; at the Xaa438, the S is replaced with the I; at the Xaa505, the F is replaced with the L; 3) 9 replacements, wherein at the Xaa143, the L is replaced with the P; at the Xaa244, the L is replaced with the V; at the Xaa326, the K is replaced with the C; at the Xaa426, the L is replaced with the F; at the Xaa432, the F is replaced with the L; at the Xaa433, the T is replaced with the A; at the Xaa435, the L is replaced with the S; at the Xaa438, the S is replaced with the I; at the Xaa505, the F is replaced with the L; 4) 9 replacements, wherein at the Xaa143, the L is replaced with the P; at the Xaa244, the L is replaced with the I; at the Xaa326, the K is replaced with the C; at the Xaa426, the L is replaced with the F; at the Xaa432, the F is replaced with the L; at the Xaa433, the T is replaced with the A; at the Xaa435, the L is replaced with the S; at the Xaa438, the S is replaced with the I; at the Xaa505, the F is replaced with the L; 5) 9 replacements, wherein at the Xaa143, the L is replaced with the P; at the Xaa248, the L is replaced with the E; at the Xaa326, the K is replaced with the C; at the Xaa426, the L is replaced with the F; at the Xaa432, the F is replaced with the L; at the Xaa433, the T is replaced with the A; at the Xaa435, the L is replaced with the S; at the Xaa438, the S is replaced with the I; at the Xaa505, the F is replaced with the L; 6) 9 replacements, wherein at the Xaa143, the L is replaced with the P; at the Xaa248, the L is replaced with the N; at the Xaa326, the K is replaced with the C; at the Xaa426, the L is replaced with the F; at the Xaa432, the F is replaced with the L; at the Xaa433, the T is replaced with the A; at the Xaa435, the L is replaced with the S; at the Xaa438, the S is replaced with the I; at the Xaa505, the F is replaced with the L; 7) 9 replacements, wherein at the Xaa143, the L is replaced with the P; at the Xaa248, the L is replaced with the A; at the Xaa326, the K is replaced with the C; at the Xaa426, the L is replaced with the F; at the Xaa432, the F is replaced with the L; at the Xaa433, the T is replaced with the A; at the Xaa435, the L is replaced with the S; at the Xaa438, the S is replaced with the I; at the Xaa505, the F is replaced with the L; 8) 9 replacements, wherein at the Xaa143, the L is replaced with the P; at the Xaa248, the L is replaced with the W; at the Xaa326, the K is replaced with the C; at the Xaa426, the L is replaced with the F; at the Xaa432, the F is replaced with the L; at the Xaa433, the T is replaced with the A; at the Xaa435, the L is replaced with the S; at the Xaa438, the S is replaced with the I; at the Xaa505, the F is replaced with the L; 9) 9 replacements, wherein at the Xaa143, the L is replaced with the P; at the Xaa277, the F is replaced with the L; at the Xaa326, the K is replaced with the C; at the Xaa426, the L is replaced with the F; at the Xaa432, the F is replaced with the L; at the Xaa433, the T is replaced with the A; at the Xaa435, the L is replaced with the S; at the Xaa438, the S is replaced with the I; at the Xaa505, the F is replaced with the L; 10) 9 replacements, wherein at the Xaa143, the L is replaced with the P; at the Xaa277, the F is replaced with the V; at the Xaa326, the K is replaced with the C; at the Xaa426, the L is replaced with the F; at the Xaa432, the F is replaced with the L; at the Xaa433, the T is replaced with the A; at the Xaa435, the L is replaced with the S; at the Xaa438, the S is replaced with the I; at the Xaa505, the F is replaced with the L; 11) 9 replacements, wherein at the Xaa143, the L is replaced with the P; at the Xaa277, the F is replaced with the Y; at the Xaa326, the K is replaced with the C; at the Xaa426, the L is replaced with the F; at the Xaa432, the F is replaced with the L; at the Xaa433, the T is replaced with the A; at the Xaa435, the L is replaced with the S; at the Xaa438, the S is replaced with the I; at the Xaa505, the F is replaced with the L; 12) 9 replacements, wherein at the Xaa143, the L is replaced with the P; at the Xaa277, the F is replaced with the I; at the Xaa326, the K is replaced with the C; at the Xaa426, the L is replaced with the F; at the Xaa432, the F is replaced with the L; at the Xaa433, the T is replaced with the A; at the Xaa435, the L is replaced with the

Assignees

Inventors

Classifications

  • by oxidation/reduction reactions · CPC title

  • Unspecific monooxygenase (1.14.14.1) · CPC title

  • C12N9/0071Primary

    acting on paired donors with incorporation of molecular oxygen (1.14) · CPC title

  • Heterorings having nitrogen atoms as the only ring heteroatoms · CPC title

  • Bacteria or Actinomycetales {; using bacteria or Actinomycetales} · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11345900B2 cover?
A monooxygenase having an amino acid sequence obtained by mutation of the amino acid sequence shown in SEQ ID NO:2 is disclosed. The use of the monooxygenase of the present invention in production of chiral sulfoxide-based drugs has advantages including mild reaction conditions, environmental friendliness, high yield, high optical purity of products, less peroxide products, and the like, and th…
Who is the assignee on this patent?
Jiangsu Aosaikang Pharm Co Ltd, Univ East China Science & Tech
What technology area does this patent fall under?
Primary CPC classification C12Y114/14001. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue May 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).